Published in Ugeskr Laeger on April 22, 1996
Exercise training and the progression of chronic renal failure. Nephron (1997) 1.73
Hormonal contraception and risk of cancer. Hum Reprod Update (2010) 1.69
Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives: a rebuttal. J Thromb Haemost (2013) 1.12
Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception (1993) 1.01
The short-term effects of a low-dose oral contraceptive on glucose metabolism, plasma lipids and blood clotting factors. Contraception (1983) 0.95
Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. Hum Reprod (2002) 0.87
Preconception counseling and contraception after gestational diabetes. Diabetes (1991) 0.85
Significant reduction of the antiatherogenic effect of estrogen by long-term inhibition of nitric oxide synthesis in cholesterol-clamped rabbits. J Clin Invest (1997) 0.84
Oral contraception and insulin sensitivity: in vivo assessment in normal women and women with previous gestational diabetes. J Clin Endocrinol Metab (1987) 0.84
The number of oogonia and somatic cells in the human female embryo and fetus in relation to whether or not exposed to maternal cigarette smoking. Hum Reprod (2009) 0.84
Cigarette smoking during early pregnancy reduces the number of embryonic germ and somatic cells. Hum Reprod (2010) 0.83
Triphasic oral contraception: metabolic effects in normal women and those with previous gestational diabetes. Am J Obstet Gynecol (1985) 0.81
Age determination enhanced by embryonic foot bud and foot plate measurements in relation to Carnegie stages, and the influence of maternal cigarette smoking. Hum Reprod (2009) 0.81
Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study. BJOG (2003) 0.81
Polycystic ovary syndrome: infertility, cardiovascular, metabolic and obstetrical risks, laboratory and clinical outcomes -- the PICOLO Study. Gynecol Endocrinol (2012) 0.80
Menstrual cycle and skin reactivity. J Am Acad Dermatol (1991) 0.80
Metabolic and fibrinolytic response to changed insulin sensitivity in users of oral contraceptives. Contraception (1999) 0.79
Kingella kingae osteomyelitis mimicking an eosinophilic granuloma. Acta Paediatr Scand (1982) 0.78
Intrauterine contraceptive devices for diabetics. Lancet (1982) 0.78
Contraception for women with diabetes: an update. Baillieres Clin Obstet Gynaecol (1991) 0.78
Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. Am J Obstet Gynecol (1999) 0.78
A partial estrogen receptor agonist with strong antiatherogenic properties without noticeable effect on reproductive tissue in cholesterol-fed female and male rabbits. Arterioscler Thromb Vasc Biol (1997) 0.78
Desogestrel and gestodene in oral contraceptives: 12 months' assessment of carbohydrate and lipoprotein metabolism. Obstet Gynecol (1991) 0.78
Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. Am J Obstet Gynecol (1990) 0.77
Intrauterine devices in nulliparous women. Adv Contracept (1991) 0.77
Hormonal contraception in women with IDDM. Influence on glycometabolic control and lipoprotein metabolism. Diabetes Care (1995) 0.77
Role of progestins with partial antiandrogenic effects. Climacteric (2004) 0.77
Consequences of intrauterine contraception in diabetic women. Fertil Steril (1984) 0.77
CO2-laser vaporization of human papillomavirus (HPV)-induced abnormal cervical smears. A simple and effective solution to a recurrent clinical problem. Clin Exp Obstet Gynecol (1991) 0.77
Polycystic ovary syndrome and low-grade inflammation with special reference to YKL-40. Gynecol Endocrinol (2014) 0.77
Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women. Am J Obstet Gynecol (1993) 0.76
Low dosage oral contraception in women with previous gestational diabetes. Obstet Gynecol (1982) 0.76
Contraception guidance in women with pre-existing disturbances in carbohydrate metabolism. Eur J Contracept Reprod Health Care (1998) 0.76
A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional-dose regimen. Climacteric (2004) 0.75
[Cardiac death resulting from Reiter's syndrome]. Ugeskr Laeger (1988) 0.75
Comparative trial of the effects on glucose tolerance and lipoprotein metabolism of two new oral contraceptives containing gestoden and desogestrel. Acta Obstet Gynecol Scand (1988) 0.75
Increased concentration of circulating atrial natriuretic peptide during normal pregnancy. Eur J Obstet Gynecol Reprod Biol (1988) 0.75
Prolactin and glucose tolerance in normal and gestational diabetic pregnancy. Obstet Gynecol (1986) 0.75
Oral contraceptives and insulin receptor binding in normal women and those with previous gestational diabetes. Am J Obstet Gynecol (1986) 0.75
Cardiovascular disease and oral contraceptive use. Eur J Contracept Reprod Health Care (1998) 0.75
[Hormonal contraception with ethinylestradiol and gestoden. The effects on glucose tolerance and lipid metabolism]. Ugeskr Laeger (1987) 0.75
[Intrauterine contraception in nulliparas with Nullip]. Ugeskr Laeger (1981) 0.75
Assessment of endothelial function during oral contraception in women with insulin-dependent diabetes mellitus. Metabolism (1994) 0.75
Balance of coagulation activity with fibrinolysis during use of oral contraceptives in women with insulin-dependent diabetes mellitus. Int J Fertil Menopausal Stud (1995) 0.75
Anti-cardiolipin antibodies (IgG and IgA) in women with recurrent fetal loss correlate to clinical and serological characteristics of SLE. Acta Obstet Gynecol Scand (1993) 0.75
[Pre-eclampsia--on the track of a new principle?]. Ugeskr Laeger (1987) 0.75
Hormone therapy affects plasma measures of factor VII-activating protease in younger postmenopausal women. Climacteric (2010) 0.75
[Endometriosis--new perspectives. 2. Classification and treatment]. Ugeskr Laeger (1989) 0.75
[Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno-2 study]. Ugeskr Laeger (1999) 0.75
Effects of contraceptive steroids on cardiovascular risk factors in women with insulin-dependent diabetes mellitus. Am J Obstet Gynecol (1994) 0.75
No influence of proinsulin and insulin on plasma levels of plasminogen activator inhibitor type 1 and tissue plasminogen activator in young women before and during intake of contraceptive steroids. Metabolism (1996) 0.75
[Residual function in the ovary during low-dose oral contraceptive treatment]. Ugeskr Laeger (1989) 0.75
[Endometriosis--new perspectives. 1. Pathology and physiopathology]. Ugeskr Laeger (1989) 0.75
[Letter: Is the tourist information about malaria prevention sufficient?]. Ugeskr Laeger (1976) 0.75
[Anti-phospholipid antibodies and habitual abortion]. Ugeskr Laeger (1991) 0.75
[Experience with a copper-silver IUD, Cu-T 2200W]. Ugeskr Laeger (1978) 0.75
Contraception in diabetic women. Acta Endocrinol Suppl (Copenh) (1986) 0.75
Estrogen receptor 1 haplotype does not regulate oral contraceptive-induced changes in haemostasis and inflammation risk factors for venous and arterial thrombosis. Hum Reprod (2006) 0.75
Oral contraceptives in diabetic women: metabolic effects of four compounds with different estrogen/progestogen profiles. Fertil Steril (1986) 0.75
Update on the metabolic effects of oral contraceptives. J Obstet Gynaecol (Lahore) (1986) 0.75
[Clean intermittent self catheterization]. Ugeskr Laeger (1987) 0.75
35 years with oral contraception: the Ghost of Pill Scare still rides! Eur J Contracept Reprod Health Care (1996) 0.75
The influence on the pituitary-ovarian function, cervical mucus and vaginal cytology of a new progestational compound. Contraception (1976) 0.75
Hormonal contraception in diabetic women: acceptability and influence on diabetes control and ovarian function of a nonalkylated estrogen/progestogen compound. Contraception (1985) 0.75
CO2 laser vaporization in the treatment of cervical human papillomavirus infection in women with abnormal Papanicolaou smears. Gynecol Obstet Invest (1992) 0.75
[Hemostatic balance during treatment with the newest contraceptives]. Ugeskr Laeger (1994) 0.75
[Post-menopausal hormone substitution and ischemic heart disease]. Ugeskr Laeger (1999) 0.75
[IUD and induced abortion]. Ugeskr Laeger (1976) 0.75